Tallac Therapeutics Presents New Data on Toll-like Receptor Agonist Antibody Conjugate, TAC-001, at the 2021...
Harnessing the power of innate and adaptive immunity to fight cancer
About US
Tallac Therapeutics™, founded in 2018 is a privately held biopharmaceutical company based in the San Francisco Bay Area. Our multi-disciplinary team is rapidly advancing the company’s lead programs in cancer toward clinical trials in multiple indications.




Science
Despite the success of checkpoint inhibitors and adoptive CAR-T therapies, only a fraction of cancer patients benefit. Novel therapies engaging both innate and adaptive immune response may produce more robust and durable anti-cancer immunity. We developed a novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent TLR9 agonist (T-CpG) for targeted immune activation via systemic administration. We are advancing a pipeline of therapies that enable innovative therapeutic approaches for multiple solid tumor malignancies.
News
We are excited to share our latest news and scientific publications.
TallacTherapeutics announces AACR 2021 presentation on preclinical data for TAC-001, the lead program from our...
Companies will combine their unique scientific and technical expertise to develop a first-in-class anti-SIRPα antibody...